মূল্য
দামগুলো আনুমানিক MRP এবং ফার্মেসিভেদে ভিন্ন হতে পারে। সর্বশেষ নথিভুক্ত দামের সাথে তুলনা করে ট্রেন্ড দেখানো হয়।
সব দামের পরিবর্তন →এই ওষুধে সাশ্রয় করুন
একই সক্রিয় উপাদান — 33% পর্যন্ত কম দিন
এই ব্র্যান্ডগুলোতে একই সক্রিয় উপাদান আছে (Lapatinib). একই মাত্রা ও ধরন। বদলানোর আগে আপনার ডাক্তার বা ফার্মাসিস্টের সাথে নিশ্চিত হয়ে নিন।
ইঙ্গিত ও ব্যবহার
Certus এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
প্রাপ্তবয়স্ক:
HER2-Positive Metastatic Breast Cancer: The recommended dose of Lapatinib is 1,250 mg given orally once daily on Days 1-21 continuously in combination with Capecitabine 2,000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21-day cycle. Lapatinib should be taken at least one hour before or one hour after a meal. The dose of Lapatinib should be once daily (5 tablets administered all at once); dividing the daily dose is not recommended. Capecitabine should be taken with food or within 30 minutes after food. If a day’s dose is missed, the patient should not double the dose the next day. Treatment should be continued until disease progression or unacceptable toxicity occurs.Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer: The recommended dose of Lapatinib is 1,500 mg given orally once daily continuously in combination with Letrozole. When coadministered with Lapatinib, the recommended dose of Letrozole is 2.5 mg once daily. Lapatinib should be taken at least one hour before or one hour after a meal. The dose of Lapatinib should be once daily (6 tablets administered all at once); dividing the daily dose is not recommended.Pediatric Use: The safety and effectiveness of Lapatinib in pediatric patients have not been established.
পার্শ্বপ্রতিক্রিয়া
The most common adverse reactions during treatment with Laparen plus Capecitabine were diarrhea, palmar-plantar erythrodysesthesia, nausea, rash, vomiting, and fatigue. The most common adverse reactions during treatment with Laparen plus Letrozole were diarrhea, rash, nausea, and fatigue.
সতর্কতা ও নিষেধাজ্ঞা
সতর্কতা ও সাবধানতা
Decreased Left Ventricular Ejection Fraction: Laparen has been reported to decrease LVEF. In clinical trials, the majority (greater than 57%) of LVEF decreases occurred within the first 12 weeks of treatment; however, data on longterm exposure are limited. Caution should be taken if Laparen is to be administered to patients with conditions that could impair left ventricular function. LVEF should be evaluated in all patients prior to initiation of treatment with Laparen to ensure that the patient has a baseline LVEF that is within the institution’s normal limits. LVEF should continue to be evaluated during treatment with Laparen to ensure that LVEF does not decline below the institution’s normal limits.Hepatotoxicity: Hepatotoxicity [alanine aminotransferase, (ALT) or aspartate aminotransferase, (AST) greater than 3 times the upper limit of normal (ULN) and total bilirubin greater than 2 times the ULN] has been observed in clinical trials (less than 1% of patients) and postmarketing experience. The hepatotoxicity may be severe and deaths have been reported. Causality of the deaths is uncertain. The hepatotoxicity may occur days to several months after initiation of treatment. Liver function tests (transaminases, bilirubin, and alkaline phosphatase) should be monitored before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. If changes in liver function are severe, therapy with Laparen should be discontinued and patients should not be retreated with Laparen. Patients With Severe Hepatic Impairment: If Laparen is to be administered to patients with severe preexisting hepatic impairment, dose reduction should be considered. In patients who develop severe hepatotoxicity while on therapy, Laparen should be discontinued and patients should not be retreated with Laparen.Diarrhea: Diarrhea has been reported during treatment with Laparen. The diarrhea may be severe, and deaths have been reported. Diarrhea generally occurs early during treatment with Laparen, with almost half of those patients with diarrhea first experiencing it within 6 days. This usually lasts 4 to 5 days. Laparen-induced diarrhea is usually low-grade, with severe diarrhea of NCI CTCAE Grades 3 and 4 occurring in less than 10% and less than 1% of patients, respectively. Early identification and intervention is critical for the optimal management of diarrhea. Patients should be instructed to report any change in bowel patterns immediately. Prompt treatment of diarrhea with antidiarrheal agents (such as Loperamide) after the first unformed stool is recommended. Severe cases of diarrhea may require administration of oral or intravenous electrolytes and fluids, use of antibiotics such as Fluoroquinolones (especially if diarrhea is persistent beyond 24 hours, there is fever, or Grade 3 or 4 neutropenia), and interruption or discontinuation of therapy with Laparen.Interstitial Lung Disease/Pneumonitis: Laparen has been associated with interstitial lung disease and pneumonitis in monotherapy or in combination with other chemotherapies. Patients should be monitored for pulmonary symptoms indicative of interstitial lung disease or pneumonitis. Laparen should be discontinued in patients who experience pulmonary symptoms indicative of interstitial lung disease/pneumonitis which are greater than or equal to Grade 3 (NCI CTCAE v3.0). QT Prolongation: A concentration-dependent QT prolongation has been associated with Laparen. Monitor patients who have or may develop prolongation of QTc during treatment with Laparen. These conditions include patients with hypokalemia or hypomagnesemia, with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products with known risk for QT prolongation/ Torsades de Pointes (TdP), and cumulative high-dose anthracycline therapy. Correct hypokalemia or hypomagnesemia prior to Laparen administration.Severe Cutaneous Reactions: Severe cutaneous reactions have been reported with Laparen. If life-threatening reactions such as erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis (e.g., progressive skin rash often with blisters or mucosal lesions) are suspected, discontinue treatment with Laparen.
নিষেধাজ্ঞা
Lapatinib is contraindicated in patients with known severe hypersensitivity (e.g., anaphylaxis) to this product or any of its components.